Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 46

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 46
---
Plan, all of which may be issued pursuant to the exercise of incentive stock options.

Stock-based
compensation

The
fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected
volatility, expected dividends, expected term, and the risk-free interest rate. Expected price volatility is based on the historical
volatilities of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several
public companies in the biotech industry similar to the Company in size, stage of life cycle and product indications. The Company intends
to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information
regarding the volatility of the Company’s own stock price becomes available, or unless circumstances change such that the identified
companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would
be utilized in the calculation.

Expected
term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of
the vesting term plus contract term. The risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant.
The Company recognizes forfeitures as they occur.

    11

The
following is option activity during the nine months ended September 30, 2025 and September 30, 2024:

 Schedule
of option activity

    Number of Shares  
    Weighted
                                                                                Average Exercise Price  Per Share  
    Weighted
                                                                                Average
                                                                                Remaining
                                                                                Contractual Life (Years)  
    Aggregate
                                                                                Intrinsic
                                                                                Value 
  
    Outstanding as December 31, 2023 
     -  
    $-  
     -  
    $- 
  
    Options granted 
     2,370,170  
    $5.02  
     9.9  
    $- 
  
    Expired 
     -  
     -  

    Forfeitures 
     -  
     -  

    Outstanding as September 30, 2024 
     2,370,170  
    $5.02  
     9.9  
    $- 

    Outstanding as December 31, 2024 
     2,352,670